Printed from Voxsanity (voxsanity.com.au) — NCT06706219 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT06706219
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing to take part, understand what the study involves, and are able to sign a written consent form.
- Men or women between 18 and 70 years of age (inclusive) at the time of signing the consent form.
- People with a good general health and activity level, rated 0 or 1 on a standard performance scale (ECOG PS), meaning they are fully active or have minor limitations but can still carry out light work.
- People who have been confirmed by tissue or cell testing to have stage III non-small cell lung cancer (NSCLC) that cannot be treated with surgery, as determined by the study doctor, and staged according to a specific international staging system (AJCC/UICC 8th edition).
- People who are able to provide a tumour tissue sample — either one collected within the past 6 months or a freshly obtained one.
- People whose lungs are working at a minimum level as measured by breathing tests within the past 3 months (FEV1 greater than 1.0 L and FEV1% greater than 40%) (confirm with trial site).
- People who have at least one measurable tumour that can be detected on a CT or MRI scan, assessed within 28 days before starting the study treatment.
- People whose blood counts, liver, kidneys, heart, and clotting function all meet specific minimum levels as measured by blood tests done within 14 days before starting treatment, including: sufficient white blood cells, lymphocytes, platelets, and haemoglobin without recent blood transfusions or growth factor support; liver enzyme and bilirubin levels within acceptable ranges; kidney function meeting a minimum clearance rate; normal clotting levels; and heart pumping function of at least 50%.
- Women who could become pregnant must have a negative pregnancy test within 72 hours before starting the study drug, and must use reliable contraception (such as an intrauterine device, oral contraceptive pill, or condom) during the trial and for 90 days after the last dose; male participants whose partners could become pregnant must use condoms during the trial and for 30 days after the study ends.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer has been confirmed as a mixed type involving small cell and non-small cell cancer, large cell neuroendocrine carcinoma, or sarcomatoid carcinoma.
- People whose tumour has specific genetic changes — EGFR gene mutations or ALK/ROS1 gene rearrangements.
- People who have previously had any systemic anti-cancer treatment for NSCLC (including experimental treatments in other trials) or prior radiation therapy to the chest.
- People who have had another cancer in the past 3 years, except for certain cancers that were fully treated with local therapy (such as some skin cancers or cervical carcinoma in situ).
- People with certain heart or blood vessel conditions, including: a heart attack, unstable chest pain, serious heart failure, poorly controlled irregular heartbeat, stroke, or other serious heart or brain vessel events within the past 6 months; a history of heart muscle disease such as myocarditis or cardiomyopathy; a blood clot in a deep vein within the past 3 months (unless it has been stable with treatment for at least 2 weeks), a blood clot in the lungs, or other serious clotting events; or a life-threatening or surgically significant condition of the major blood vessels (such as aortic aneurysm) within the past 6 months.
- People with poorly controlled diabetes (high fasting blood sugar on two consecutive tests) or poorly controlled high blood pressure, as judged by the study doctor.
- People with a history of non-infectious lung inflammation (interstitial lung disease or pneumonitis) that required steroid treatment, current such conditions, or suspected lung inflammation seen on scans at screening that cannot be ruled out.
- People with significant lung problems caused by other lung conditions, including a blood clot in the lungs within the past 3 months, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, fluid around the lungs, or autoimmune or inflammatory conditions that could affect the lungs (such as rheumatoid arthritis, Sjögren's syndrome, or sarcoidosis).
- People with active inflammatory bowel disease, bowel obstruction, severe ulcers, a hole in the gut, an abdominal abscess, or active bleeding in the digestive tract.
- People with active autoimmune diseases that required systemic treatment (such as disease-modifying drugs, immunosuppressants, or steroid doses above 10 mg/day prednisone or equivalent) within the past 2 years; or people who have received such treatments within 2 weeks before starting the study.
- People with known active tuberculosis (TB), or suspected active TB that has not been ruled out by medical evaluation.
- People who have previously received an organ transplant or bone marrow/stem cell transplant from another person.
- People with active hepatitis B (with a specific level of virus detectable in the blood) or active hepatitis C (with virus detectable in the blood). Note: people who test positive for the hepatitis B surface antigen are required to receive antiviral treatment throughout the study.
- People who are known to be HIV positive or have a history of AIDS; people with a known active syphilis infection.
- People with a known allergy or serious sensitivity to any of the study drugs (disitamab vedotin, toripalimab, platinum-based chemotherapy, pemetrexed, paclitaxel, or docetaxel) or their ingredients, or people with a history of severe allergic reactions to other monoclonal antibody treatments.
- People who have had major surgery within 4 weeks before starting the study, or who are expected to need major surgery during the study.
- People who have had a serious infection within 4 weeks before starting the study (including infections requiring hospitalisation, sepsis, or severe pneumonia), or who have an active infection requiring antibiotic or antiviral treatment within 2 weeks before starting.
- People who have received non-specific immune-boosting therapies (such as interferon or IL-2) or certain approved traditional Chinese medicine preparations with anti-cancer indications within 2 weeks before starting the study.
- People who have received a live vaccine within 30 days before starting the study, or who plan to receive a live vaccine during the study.
- People whose condition has deteriorated significantly during the screening period before the first dose, such as a notable decline in general health and function.
- Women who are pregnant or breastfeeding.
- People with significant non-cancer-related medical conditions, or conditions caused by the tumour (such as extreme weight loss or a certain type of abnormal blood reaction), that may pose serious health risks or make it difficult to assess how someone is doing in the trial.
- People with documented severe dry eye syndrome, severe eyelid gland disease or eyelid inflammation, or a history of corneal eye disease that affects healing.
- People who have any other condition that, in the study doctor's judgement, could interfere with the study, put the person at risk, or make results difficult to interpret.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: +8613873123436
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Hunan Province Tumor Hospital
Registry
ClinicalTrials.gov
Start date
10 May 2026
Est. completion
30 November 2028
Where this trial is recruiting
🇨🇳 China
Primary endpoints
18m EFS rate; Surgical Conversion Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.